https://www.medisonpharma.com/uncategorized/alnylam-pharmaceuticals-and-medison-pharma-partner-to-commercialize-rnai-therapeutics-in-israel/ 2019-01-20T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/bridgebio-pharmas-origin-biosciences-enters-partnership-with-medison/ 2019-12-17T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/alpha-tau-medical-announces-exclusive-distribution-arrangement-with-medison-canada/ 2020-04-06T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/beigene-and-medison/ 2020-05-20T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-and-alpha-tau-medical-announce-a-collaboration/ 2020-06-14T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-and-deciphera-pharmaceuticals/ 2020-11-05T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/rigel-and-medison-announce-health-canada-approval-of-tavalisse/ 2020-11-22T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/amryt-and-medison-pharma-sign-multi-regional-distribution-agreements-in-canada-and-israel/ 2021-02-03T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/amryt-and-medison-pharma-sign-distribution-agreement-for-myalepta-metreleptin-in-canada/ 2021-03-07T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/moderna-and-medison/ 2021-06-06T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/rhythm-pharmaceuticals-and-medison/ 2021-07-21T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/immunocore-and-medison-pharma/ 2021-10-17T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/immunocore-and-medison-pharma-partner/ 2021-12-06T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/victor-papamoniodis-joins-medison/ 2022-01-25T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/beigene-and-medison-announce-approval-and-national-reimbursement-in-israel-for-brukinsa-zanubrutinib-for-the-treatment-of-waldenstroms-macroglobulinemia/ 2022-03-14T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/hansa-biopharma-and-medison-pharma-announce-marketing-authorization-in-israel-for-idefirix-imlifidase-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients/ 2022-03-27T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-announces-extension-of-multi-territorial-agreement-with-immunocore-and-expansion-into-australia-and-new-zealand/ 2022-05-22T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-announces-multi-regional-partnership-agreement-with-argenx/ 2022-06-05T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-announces-the-expansion-of-its-partnership-with-albireo-to-a-multi-regional-agreement-to-commercialize-odevixibat-in-canada-and-israel/ 2022-08-15T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/hansa-biopharma-and-medison-pharma-announce-positive-reimbursement-decision-in-poland-for-idefirix-in-highly-sensitized-kidney-transplant-patients/ 2022-08-21T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-announces-expansion-of-the-multi-territorial-agreement-with-immunocore-into-latin-america/ 2022-11-08T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/sarah-otten-joins-medison-pharma-as-vp-gm-americas-region/ 2023-01-08T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/alnylam-pharmaceuticals-and-medison-pharma-announce-the-expansion-of-their-collaboration-to-a-multi-regional-partnership-to-commercialize-rnai-therapeutics/ 2023-03-08T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/ipsen-and-medison-pharma-announce-health-canada-approval-of-bylvay-odevixibat-for-the-treatment-of-pruritus-due-to-progressive-familial-intrahepatic-cholestasis-pfic/ 2023-11-12T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-announces-agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries/ 2024-01-07T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/pbs-listing-for-australians-with-unresectable-or-metastatic-uveal-melanoma1/ 2024-01-31T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-and-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-partnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in-additional-latam-and-apac-markets-including/ 2024-04-29T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/pbs-listing-for-australians-with-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/ 2024-07-31T21:00:00+00:00 https://www.medisonpharma.com/uncategorized/medison-pharma-and-immunocore-announce-anvisa-approval-of-kimmtrak-tebentafuspe-for-the-treatment-of-hla-a0201-positive-adults-with-unresectable-or-metastatic-uveal-melanoma-in-brazil1/ 2025-03-17T22:00:00+00:00 https://www.medisonpharma.com/uncategorized/amvuttra-vutrisiran-is-now-listed-on-the-pharmaceutical-benefits-scheme-pbs-for-eligible-australians-with-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy-1/ 2025-04-30T21:00:00+00:00 https://www.medisonpharma.com/%d7%9b%d7%9c%d7%9c%d7%99/medison-expands-global-leadership-team-with-chief-business-officer-and-chief-legal-compliance-officer/ 2025-06-18T14:59:39+00:00 https://www.medisonpharma.com/%d7%9b%d7%9c%d7%9c%d7%99/health-canada-approves-bylvaytm-odevixibat-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome/ 2025-09-25T07:57:34+00:00 https://www.medisonpharma.com/%d7%9b%d7%9c%d7%9c%d7%99/oxlumo-lumasiran-is-now-listed-on-the-pharmaceutical-benefits-scheme-pbs-for-eligible-australians-with-primary-hyperoxaluria-type-1ph1-1/ 2025-10-01T10:18:32+00:00 https://www.medisonpharma.com/%d7%9b%d7%9c%d7%9c%d7%99/medison-strengthens-its-global-commercialization-platform-appoints-francis-wan-as-vp-gm-asia-pacific/ 2025-10-24T07:45:42+00:00 https://www.medisonpharma.com/%d7%9b%d7%9c%d7%9c%d7%99/givlaari-givosiran-is-now-listed-on-the-pharmaceutical-benefits-scheme-pbs-for-eligible-australians-with-acute-hepatic-porphyria-ahp1/ 2026-04-02T11:45:41+00:00